Evidence map›Paper›PMID 40497061›Full record

ArticlePublic health challenges2024

Overcoming barriers to COVID-19 herd immunity in Afghanistan.

Mohammad Faisal Wardak, Ali Rahimi, Don Eliseo Lucero-Prisno, Adriana Viola Miranda

Abstract read
In one paragraph

Article in Public health challenges, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammad Faisal WardakScientific Research Center Jami University Herat Afghanistan.
Ali RahimiScientific Research Center Jami University Herat Afghanistan.ORCID https://orcid.org/0000-0001-5821-9177
Don Eliseo Lucero-PrisnoDepartment of Global Health and Development London School of Hygiene and Tropical Medicine London UK.ORCID https://orcid.org/0000-0002-2179-6365
Adriana Viola MirandaFaculty of Medicine Universitas Indonesia Jakarta Indonesia.ORCID https://orcid.org/0000-0001-8548-1592

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Afghanistan faces numerous obstacles in its endeavor to achieve herd immunity against COVID-19. Inadequate resources, vaccine hesitancy, and the new government's lack of international recognition have impeded the country and harmed vaccine procurement and distribution. Although the recent power shift has led to a more secure situation, the country's vaccination coverage remains at 44.05% as of November 26, 2023. The main hurdles to herd immunity include limited vaccine accessibility, extensive vaccine hesitancy, an inefficient cold chain system causing high vaccine wastage rates, substandard service delivery, recent restrictions on women's healthcare access, low health literacy, and a weakened economy owing to decades of conflict and international sanctions. This article assesses vaccination progress, and herd immunity barriers, and provides solutions to overcome them in Afghanistan. A comprehensive approach is required, which involves enhancing public awareness of the benefits of vaccination, debunking vaccine-related misconceptions through the media, expanding vaccine accessibility especially in remote areas, increasing vaccination personnel, promoting the cold chain and delivery system, reversing the ban on women's education and employment, boosting the economy, and increasing the inflow of humanitarian aid by lifting international sanctions. Successfully implementing these measures can help Afghanistan overcome obstacles to herd immunity, leading the country toward a safer and healthier future.

Indexed as

AfghanistanCOVID‐19herd immunitypandemicvaccination

Identifiers

PMID40497061
PMCPMC12060757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.